Abstract
To describe an unusual immune-related adverse event (irAE), acquired generalized lipodystrophy (AGL), from checkpoint inhibitor therapy in a patient treated with pembrolizumab. This is a case report of a 67-year-old male with metastatic melanoma who was treated with pembrolizumab. Prior to pembrolizumab, the patient was treated with another immune-checkpoint inhibitor and developed autoimmune hemolytic anemia. After starting pembrolizumab, he developed a scrotal mass consistent with panniculitis and after several subsequent cycles, he developed AGL. Loss of subcutaneous fat, unexplained weight loss in combination with worsening insulin resistance and worsening hypertriglyceridemia after initiation of pembrolizumab were consistent with AGL. Autoimmune disorders and other etiologies were ruled out. Despite this irAE, the patient continued to receive pembrolizumab given stabilization of melanoma with treatment. We report the second case of a patient who developed AGL secondary to pembrolizumab, and the fourth case to report such complication secondary to antiprogrammed cell death receptor-1 inhibitors. As use of checkpoint inhibitors becomes more common to treat several types of cancer, it is vital for clinicians to recognize thes...Continue Reading
References
Sep 2, 1998·Immunologic Research·Y LevyY Shoenfeld
Mar 19, 2004·The New England Journal of Medicine·Abhimanyu Garg
Feb 28, 2006·Journal of Neurology·Antonie Giaever Beiske, Kjell-Morten Myhr
Dec 20, 2008·PPAR Research·Jussi Sutinen
Nov 10, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Jean L ChanPhillip Gorden
Oct 7, 2016·The Journal of Clinical Endocrinology and Metabolism·Rebecca J BrownTohru Yorifuji
Oct 21, 2016·Cancer Immunology, Immunotherapy : CII·Young Kwang ChaeFrancis Giles
Jul 10, 2017·Cancer Treatment Reviews·Mario SznolCaroline Robert
Apr 13, 2018·Endocrine·Rebecca J BrownPhillip Gorden
Apr 29, 2018·Journal of Endocrinological Investigation·D Araújo-Vilar, F Santini
Oct 5, 2018·Frontiers in Immunology·Fernando CorvilloMargarita López-Trascasa
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Iosune BaraibarEduardo Castanon
Feb 20, 2019·The Journal of Clinical Endocrinology and Metabolism·Camila Kruschewsky FalcaoMilena Gurgel Teles
Mar 1, 2019·Endocrine Journal·Sumie OkahataTeruo Shiba
May 12, 2019·The British Journal of Dermatology·N HaddadUNKNOWN PATIO group
Aug 23, 2019·Diabetes Care·Alexandre JehlEmmanuel Disse